
    
      About 50 patients with clinical evidence of ischemic heart disease and / or a positive
      functional study and documented stable angina pectoris (Canadian cardiovascular society
      classification (CCS)1, 2, 3 or 4), or documented silent ischemia in de-novo, native,
      previously unstented vessel in Tyumen Cardiology Center,will be randomly assigned undergoing
      implantation of Orsiro stent or Resolute Integrity stent (in a 1:1 ratio).

      All of the patients will receive 12 months dual antiplatelet therapy and they will be
      followed (at the outpatient clinic) for up to 1 year. The follow-up visits will be conducted
      at 4 months (including angiographic/OCT investigation), and 1 year post percutaneous coronary
      intervention(PCI),in order to observe the Primary Endpoint and Secondary Endpoints.
    
  